| Name | Title | Contact Details |
|---|
Paragon Biosciences invests in and launches biopharmaceutical companies to develop novel therapies for severe medical conditions which do not yet have adequate treatments. Our mission is to help people live longer, healthier lives. Paragon advances that mission through its contribution of Bioscience Innovation Capital(TM): For rare and complex diseases, Paragon analyzes the viability of potential therapies, invests in new biopharmaceutical companies to further develop promising treatments, catalyzes the progress of its portfolio companies through early-incubation services, and provides clinical and regulatory guidance by a team with a near-perfect track record of first-cycle novel drug approvals.
Revolutionary Products for Soft Tissue Replacement and Regeneration
Sekisui Diagnostics, a global provider of innovative medical diagnostics to physicians and laboratories, has been committed to improving the lives of patients for over 30 years.
OncoResponse Inc., a privately held immuno-oncology company, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to the discovery of cancer therapeutics.